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Summary
Background Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma
(cSCC), together known as keratinocyte cancers (KCs), are the commonest cancer
in white ethnic populations. Recent improvements to registry data collection in
England has allowed more accurate analysis of the epidemiology of BCC and
cSCC and for the first time we are able to provide an accurate (representative)
tumour burden for KC in the U.K.
Objectives To estimate the incidence of BCC and cSCC in the U.K.
Methods A cohort of patients with KCs between 2013 and 2015 were identified
using linkage to diagnostic codes derived from pathology reports collected into
the national cancer registry. Data from England’s cancer registry were combined
with data from Scotland, Northern Ireland and Wales. European age-standardized
incidence rates (EASRs) of the first BCC and cSCC per patient per annum (PPPA)
were calculated.
Results In the U.K, the EASR of the first BCC and cSCC PPPA in 2013–15 were
285 and 77 per 100 000 person years, respectively (211 120 KCs total in
2015). The mean annual percentage increase was 5% between 2013 and 2015
for both BCC and cSCC. By counting the first KC PPPA, we include an additional
51% KCs compared with the previous reporting technique which counts only the
first BCC and cSCC in a patient’s lifetime, yet it represents a probable underesti-
mation of 5–11% of the true tumour count.
Conclusions Based on an improved methodology, a more representative incidence
of KC is presented, which is essential to healthcare planning and will lead to
improved understanding of the epidemiology of KC.
What’s already known about this topic?
• Keratinocyte cancers (KCs) are the most common cancers affecting white ethnic
populations.
• The incidence of basal cell carcinoma (BCC) and cutaneous squamous cell carci-
noma (cSCC) is increasing worldwide including the U.K., most commonly in
elderly male Caucasian patients.
• These cancers are traditionally substantially underreported and frequently excluded
from national cancer statistics.
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What does this study add?
• Using improved data collection methods in England and validated tumour-report-
ing techniques, we report the most accurate BCC and cSCC incidence data for the
U.K. ever published.
• Identifying the first BCC and cSCC per patient per annum, the incidence of BCC
and cSCC in the U.K. (excluding Wales) was 285 and 77 per 100 000 person
years, respectively, between 2013 and 2015, with more than 210 000 KCs in the
U.K. in 2015.
Keratinocyte cancers (KCs), the collective term for basal cell
carcinomas (BCCs) and cutaneous squamous cell carcinomas
(cSCCs), are the most common cancers in the U.K. and the
most common cancers in white ethnic populations worldwide.
However, epidemiological data in the U.K. have historically
been of relatively poor quality.1–5 Due to high volume and
multiplicity of KCs, they have frequently been excluded from
national cancer registries and statistics. Previous studies have
reported that incidence rates of KCs are increasing worldwide
and evidence from local audits suggest that the rate of increase
in the U.K. may be higher than in European counterparts.6–13
Increasing tumour incidence is presumed to be a result of an
ageing population, increased ultraviolet radiation (UVR) expo-
sure with easier access to travel abroad and a higher propor-
tion of fairer skin types in the U.K. compared with other
countries,6,14 but little is known about the epidemiology of
KCs in the U.K.
The healthcare workload burden and cost of KCs is substan-
tial within dermatology departments in the U.K., where these
cancers are often seen urgently within 2 weeks of referral. In
2008, skin cancer management costs were estimated to be
between £106 and £112 million and approximately £889–
1226 per KC in England.15 A decade later, these estimates are
likely to be substantially higher, with advances in treatment
approaches and increase in patient volume. Furthermore,
despite a relatively low mortality, morbidity through cosmetic
disfigurement and functional morbidity is considerable given
that KCs are frequently multiple and most commonly located
on the face.
Despite the high volume and associated costs of KCs, lim-
ited research progress has been reported. This discrepancy was
highlighted by a U.K. Translational Research Network in Der-
matology (UKTREND) e-DELPHI exercise that assessed the
research needs of clinicians in the U.K. and identified research
into KCs as a priority area.16
In 1999, the United Kingdom and Ireland Association of
Cancer Registries (UKIACR) ruled that due to complexities in
registering multiple pathology reports accurately, only the first
BCC or cSCC per patient is reported, despite all pathology
reports now being routinely collected since 2013 in England,
Scotland and Northern Ireland.17 This rule is also used in
many cancer registries worldwide.6 The impact of this regis-
tration approach was that previous figures were clearly
significant underestimations of national incidence in the U.K.
Metachronous and synchronous BCCs and cSCCs are com-
mon.18 After a diagnosis of BCC, the 3-year risk of a subse-
quent BCC is estimated to be 44%, with 10% developing a
further BCC within 6 months.10,19–21 Likewise, after an initial
cSCC, the 5-year risk of a further cSCC is estimated to be
37%.21 Previous studies have shown that when counting all
BCCs as opposed to the first registered BCC, an additional 30–
50% of tumours are counted.10,22–24 Changes in cancer regis-
tration processes in England, including the introduction of
national automated registration have enabled the development
of a more comprehensive BCC and cSCC dataset for the first
time.
The objective of this study was to validate improved data
collection methods and report the incidence and survival for
BCC and cSCC from the cancer registry data at a national level
for the first time.
Materials and methods
Study design, setting and participants
Data were provided by the National Cancer Registration and
Analysis Service (NCRAS), England. It is mandatory for all
National Health Service pathology laboratories, and recom-
mended to all private pathology laboratories in England, to
provide all cancer pathology reports to NCRAS and NCRAS
data quality teams to ensure that pathology laboratories are
compliant. These pathology reports are combined with infor-
mation from the Patient Administration System (PAS) and
Cancer Outcomes and Services Dataset (COSD) to form a can-
cer registration record. In England, this process has been
nationalized and mostly automated since 2013; a majority of
tumours are registered based on the pathology report labora-
tory codes and text information provided. The minority that
do not meet the automated processor’s selection criteria are
manually registered.
BCCs and cSCCs were identified using the ICD-10 (Interna-
tional Classification of Diseases) site codes and ICD-02 mor-
phology and behaviour codes (Table S1, see Supporting
Information). The date of receipt of the pathology sample was
used as the date of diagnosis, to identify the first BCC and
cSCC per patient per annum (PPPA).
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Data were also provided by Information Services Division
Scotland, the Northern Ireland cancer registry and the Welsh
Cancer Intelligence & Surveillance Unit (WCISU). Welsh data
collection is acknowledged by the registry to be incomplete
(personal communication with WCISU), awaiting changes to
be enforced from 2016 data onwards. Welsh data were there-
fore excluded from the analyses, except for overall tumour
count.
Validation
To confirm the accuracy of the data and the use of the first
KC PPPA technique, a randomized selection of 500 patients
with BCC and 500 patients with cSCC in 2013 in England
were reviewed by a single dermatologist (Z.C.V.). Tumours
diagnosed in the previous calendar year, recurrences of previ-
ous tumours and incorrectly coded tumours were excluded,
e.g. Bowen disease. Additional tumours collected but not
counted with the first KC PPPA technique (i.e. more than one
tumour per annum) were analysed to provide an estimate of
how the first KC PPPA compares with manually registering all
tumours per patient and also to assess the validity of the regis-
tration process in England. Furthermore, in Scotland, because
all cSCCs are registered except in specific cases such as patients
with genetic predisposition to multiple cSCCs, Scottish data
was also used to assess the first KC PPPA technique vs. regis-
tering all tumours manually.
Variables
Patient demographics such as age (taken as a continuous vari-
able taken from day of diagnosis), sex and self-reported eth-
nicity were analysed from NCRAS, which derives information
from PAS and COSD. Deprivation quintiles were calculated
using the patient’s Lower Super Output Area at diagnosis
linked to the Index of Multiple Deprivation 2015.25
Statistical analysis
The NCRAS data were extracted using Oracle SQL developer©
version 41521 (Oracle; Redwood City, CA, U.S.A.). Micro-
soft© Excel version 2010 (Microsoft; Los Angeles, CA, U.S.A.)
and Stata© version 14 (Stata Corporation; College Station, TX,
U.S.A.) were used for statistical analyses. Randomization as
listed above was performed using a random number generator
from Excel© 2010.
European age-adjusted incidence rates (EASR) are weighted
based on European standard populations in 2013 in 5-year age
bands. The EASR of first cSCC and BCC PPPA were calculated
across sex and nations (England, Scotland and Northern Ireland).
Welsh data were excluded from EASR and age-specific rates due
to lack of completeness. The estimated annual percentage change
(EAPC) was calculated as the mean change in EASR per year.
Statistics for absolute number of deaths attributed to non-
melanoma skin cancer was as reported by the Office of
National Statistics.26
The Pohar Perme estimator was used to calculate age-stan-
dardized net survival with the ‘stns’ command in Stata 14.
This analysis was age-standardized using weights from the
International Cancer Survival Standard,27 i.e. survival was stan-
dardized based on expected survival of age- and sex-specific
groups. Life tables were obtained from the Cancer Survival
Group at the London School of Hygiene and Tropical Medi-
cine. Vital status of patients was determined until 31 Decem-
ber 2016.28
Results
Validation
Overall, an additional 51% KC tumours were identified using
first KC PPPA technique compared with identifying only the
first incident tumour of all time. Analysing the first BCC
PPPA in England 2013–15 (n = 410 716) compared with
first registered (n = 268 565) resulted in 53% further BCC
tumours recorded over 3 years. Likewise, when counting
first cSCC PPPA (n = 104 529) compared with first registered
(n = 76 977) an additional 36% cSCC tumours were
recorded.
To assess the first KC PPPA technique and use of an auto-
mated processor in England, a randomly selected cohort of
500 patients with BCC and 500 with cSCC from the English
cancer registry 2013 were selected and the number of
tumours per patient was counted. Counting the first KC PPPA
resulted in 106% fewer BCC tumours and 68% fewer cSCC
tumours (Fig. 1).
In Scotland, all cSCC tumours are registered manually except
in cases of genetic predisposition; therefore, we compared the
registered cSCC tumour count with the first KC PPPA tech-
nique in Scotland. This found an underestimation by 53% of
all cSCCs by using the first KC PPPA (Fig. 1).
Analysing the automated processing technique in England,
only 08% (8 of 1000) tumours were incorrectly coded, e.g.
Bowen disease coded as an invasive cSCC.
U.K. incidence of keratinocyte cancers
The absolute first BCC PPPA count increased in the 3-year
period from 145 817 to 166 448 in 2015 (Fig. 2a). The
EASR of first BCC PPPA in the U.K. from 2013 to 2015
was 352 per 100 000 person years (PY) in males and 219
per 100 000 PY in females. More than 85% of BCCs in the
U.K. occurred in England and the EASR was highest in Eng-
land compared with other U.K. nations (Fig. 2b). For the
U.K., the EAPC was 5% for BCC, but much lower in
Northern Ireland (03%).
The absolute count of first cSCC PPPA increased from
38 664 in 2013 to 44 672 in 2015 in the U.K. (Fig. 2c). The
EASR of first cSCC PPPA from 2013 to 2015 was 111 in men
and 42 per 100 000 PY in women with the highest rates seen
in Northern Ireland (Fig. 2d). The EAPC of cSCC was around
6% in the 3-year period.
© 2019 The Authors. British Journal of Dermatology
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Fig 2. (a–d) National tumour count and incidence rate of BCC and cSCC using the first tumour per patient per annum technique except for cSCC
data for Scotland where all cSCCs are registered; Welsh data are excluded from incidence rates due to incomplete data collection. (a) National BCC
tumour count 2013–15. (b) National EASR of BCCs 2013–15. (c) National cSCC tumour count 2013–15. (d) National EASR of cSCCs 2013–15.
EASR, European age-standardized rate; BCC, basal cell carcinoma; cSCC, cutaneous squamous cell carcinoma; LCI, lower 95% confidence interval;
UCI, upper 95% confidence interval.
500 paents with 
BCC, randomly 
selected from 2013
33 with no new BCC 
diagnosed in 2013
3 incorrectly coded 
as BCC, e.g. cSCC
26 duplicates, i.e. 
tumour diagnosed in 
previous year
4 recurrences from 
previous year
86 addional BCCs 
counted (mulple 
tumours per paent 
in same year)
Overall BCC tumour 
count underesmated 
by 10·6%
500 paents with 
cSCC, randomly 
selected from 2013
21 with no new cSCC 
diagnosed in 2013
5 incorrectly coded as 
cSCC, e.g. Bowen disease
7 duplicates, i.e. tumour 
diagnosed in previous 
year
9 recurrences from 
previous year
55 addional primary 
cSCCs (mulple tumours 
per paent in same year)
Overall cSCC tumour count 
underesmated by 6·8%
9555 cSCCs registered in 
2013–15a
9077 counted using first 
PPPA technique
Overall cSCC tumour 
count underesmated by
5·3%
aAll cSCCs are manually registered in Scotland 
except in circumstances where paents are 
genecally predisposed to developing cSCC, e.g.  
Ferguson-Smith syndrome
BCC registraon in England cSCC registraon in England cSCC registraon in Scotland
Fig 1. Analysis of first KC per patient per annum (PPPA) technique for counting keratinocyte cancers from registry data. BCC, basal cell
carcinoma; cSCC, cutaneous squamous cell carcinoma.
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Geographic incidence differences in the U.K
The incidence rates of first KC PPPA differ across the U.K. and
are highest in southern and coastal regions (Fig. 3). The high-
est BCC rates were observed in Southwest England (EASR 362
per 100 000 PY) and the lowest EASR was in Dumfries and
Galloway (39 per 100 000 PY). For cSCC, the highest rates
were observed in Southwest England and the lowest in Shet-
land (EASR 107 and 345 per 100 000 PY, respectively). Sev-
eral regions such as London and Northern Scotland have
notably lower EASR as expected.
Demographics of patients with keratinocyte cancers in
England
Patients with first all-time BCC and cSCC were more com-
monly males, with a male : female ratio 12 : 1 for BCC and
17 : 1 for cSCC (Table 1). The median age at time of inci-
dent tumour was approximately 71 years [interquartile range
(IQR) = 62–80] for BCC and 79 years (IQR 71–85) for cSCC.
The age-specific rates for both BCC and cSCC clearly increase
with age and are much higher and steeper among men than
women (Fig. 4). For both BCC and cSCC, fewer than 1% of
individuals self-reported as nonwhite, with a substantial pro-
portion of missing data (up to 34%). The distribution of the
deprivation quintiles is comparable for both tumour types
between men and women.
Body site of keratinocyte cancers in England
The majority of KCs are located in the head and neck region,
especially on the face (between 27% and 409%; Table 1).
Compared with cSCCs, BCCs tend to be more common on the
trunk and are less frequent on the upper extremities. In men,
158% of cSCCs were located on the ear whereas the ear was
affected in only 13% of women. A quarter of cSCCs in
women were located on the lower extremities, which is five-
fold more than in men. In approximately 15% of BCCs and
5% of cSCCs, body site was not reported (Table 1).
Keratinocyte cancer-specific mortality in England
The absolute number of deaths with an underlying cause of
nonmelanoma skin cancers (which includes other skin cancers
such as Merkel cell carcinomas) in England were 489 in 2013,
626 in 2014 and 624 in 2015.
Fig 3. (a) Regional BCC EASRs in the U.K. 2013–15 using the first KC PPPA technique. Welsh data are excluded due to incomplete data
collection. (b) Regional cSCC EASR in the U.K. 2013–15 using the first KC PPPA technique except in Scotland where all cSCC are registered.
Welsh data are excluded due to incomplete data collection. EASR, European age-standardized incidence rates; BCC, basal cell carcinoma; cSCC,
cutaneous squamous cell carcinoma; PPPA, per patient per annum.
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Three-year net survival was 1019% [95% confidence inter-
val (CI) 1018–1020] for BCC and 962% (95% CI 959–
966) for cSCC overall. For men, 3-year net survival was
1019% (95% CI 1018–1021) for BCC and 957% (95% CI
953–962) for cSCC. For women, 3-year net survival was
1019% (95% CI 1017–1020) for BCC and 971% (96% CI
966–976) for cSCC.
Discussion
We report the largest and most complete dataset for national
incidence of KCs ever published, with over 210 000 tumours
reported in 2015 in the U.K. With significant increases in
tumour count between 2013 and 2015, KCs represent an
overwhelming burden on the workload of healthcare
resources. KCs occur mainly in older people, and because of
steadily ageing populations, the pressure on the health service
is likely to further increase. Of note, skin cancers were four
times more common than any other cancer in the U.K. in
2015.26 This study provides much needed information, as
highlighted in recent epidemiological reviews of KC.3,7–9,29
Due to the frequent multiplicity of KCs, the UKIACR
method of counting only one tumour per patient has resulted
in substantial underestimation of national tumour counts. We
validate a technique to assess the first BCC and cSCC PPPA,
which identified 51% additional tumours compared with the
standard first registered BCC and cSCC UKIACR method. While
less accurate than manually registering all KCs, this method
allows improved incidence reports with minimal additional
workload and is easily achievable with access to pathology or
cancer registry data. Our validation study would imply that
when counting all tumours, i.e. multiple tumours per patient
per year, the true tumour count is likely to be 5–11% higher
than those provided by the first KC PPPA technique.
Table 1 Patient demographics of first all-time registered BCC and cSCC, England 2013–15
Patient demographics of first registered tumour
First BCC, n = 268 565 First cSCC n = 76 977
Male, n = 144 680 Female, n = 123 885 Male, n = 48 254 Female, n = 28 723
Age (years)
Median (IQR) 72 (63–79) 71 (60–80) 78 (71–84) 80 (71–87)
0–29 464 (03) 641 (05) 30 (01) 26 (01)
30–39 2229 (15) 3066 (25) 123 (03) 98 (03)
40–49 7685 (53) 9680 (78) 655 (14) 489 (17)
50–59 16 660 (115) 16 148 (130) 2117 (44) 1491 (52)
60–69 35 487 (245) 27 893 (225) 7352 (152) 3930 (137)
70–79 46 551 (322) 33 990 (274) 16 158 (335) 7735 (269)
80–89 30 631 (212) 25 913 (209) 17 822 (369) 10 385 (362)
90+ 4973 (34) 6554 (53) 3997 (83) 4569 (159)
Ethnicity
White 97 418 (673) 80 690 (651) 43 283 (897) 25 226 (878)
Mixed 63 (00) 69 (01) 29 (01) 22 (01)
Indian /other Asian background 108 (01) 114 (01) 73 (02) 50 (02)
Afro-Caribbean/other black background 57 (00) 61 (00) 42 (01) 38 (01)
Chinese 22 (00) 23 (00) 7 (00) 8 (00)
Other ethnic group 402 (03) 371 (03) 169 (04) 96 (03)
Unknown 46 610 (322) 42 557 (344) 4651 (96) 3283 (114)
Deprivation quintiles
1 (least deprived) 40 366 (279) 32 572 (263) 12 792 (265) 7096 (247)
2 37 363 (258) 31 004 (250) 12 451 (258) 7064 (246)
3 30 101 (208) 26 108 (211) 10 200 (211) 6295 (219)
4 21 915 (151) 20 045 (162) 7642 (158) 4825 (168)
5 (most deprived) 14 935 (103) 14 156 (114) 5169 (107) 3443 (120)
Site of first registered BCC or cSCC
Lip (cutaneous) 1491 (10) 3219 (26) 815 (17) 679 (24)
Eyelid incl. canthus 6353 (44) 8019 (65) 584 (12) 483 (17)
Ear 9439 (65) 1568 (13) 7601 (158) 363 (13)
Face 55 213 (382) 50 691 (409) 13 126 (272) 9308 (324)
Scalp/neck 11 315 (78) 8265 (67) 11 566 (240) 1669 (58)
Trunk incl. perianal 22 630 (156) 14 484 (117) 3080 (64) 2201 (77)
Upper limb incl. shoulder 9870 (68) 7479 (60) 6947 (144) 5416 (189)
Lower limb incl. hip 5637 (39) 10 951 (88) 2367 (49) 7205 (251)
Skin NOS 22 732 (157) 19 209 (155) 2168 (45) 1399 (49)
Data are n (%) unless otherwise specified. BCC, basal cell carcinoma; CI, confidence interval; cSCC, cutaneous squamous cell carcinoma;
IQR, interquartile range; NOS, not otherwise specified
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There are strengths and limitations to our study. The com-
bined U.K. registries form the largest population-based KC
registry in the world, an essential tool for assessing the epi-
demiology of these tumours and the main strength of our
study. However, inherent to large national pathology-based
cancer registries there are several potential sources of under
reporting such as use of topical and destructive treatments
without histological confirmation, miscoding or the impact of
long waiting lists. Also, there are regional differences in KC
registration within the U.K. that may have affected compar-
isons between regions. For example, all cSCCs are manually
registered in Scotland; therefore, rates will be comparatively
higher than first KC PPPA counts; despite this, rates remain
lower than in England and Northern Ireland. Due to the intro-
duction of new automated report-processing technology in
2013, the data collection prior to 2013 may be less complete.
Therefore, the increase in first registered tumours in
subsequent years may be an overestimation, but this does not
apply to first KC PPPA reporting. Because the KC registry is
based on routinely collected data and linked to other national
data sources, the granularity of the data is not always suffi-
cient, e.g. missing data in self-reported ethnicity, tumour
localization and lack of UVR exposure data.
Primary cSCCs affecting perianal sites have a different
pathogenesis, with human papillomavirus infection thought to
be an important cause rather than UVR.30 However, ICD-10
coding of perianal tumours classifies these to be coded as
‘truncal’ tumours and therefore this precludes accurate identi-
fication of these tumours.
Regarding interpretation, the distribution of recorded
anatomical sites for primary KCs differed between men and
women, which is in line with other studies.4,20 This may
relate to varying UVR exposure as a result of male-pattern
baldness and cultural preferences, i.e. shorter hair for men
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Fig 4. (a–b) Age-specific rates of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) in males and females 2013–15,
England. Using data for first tumour all time. (a) Age-specific rates of BCC. (b) Age-specific rates of cSCC.
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and women wearing dresses/skirts. This may explain why
men are more likely to develop KCs on the ear and scalp, and
for women the lower limb is preferentially affected. However,
the commonest site in both sexes for KC was the face.
The regional variations identified in KC incidence may
reflect reducing incidence with higher latitude/lower UVR
exposure. In addition, in urban areas ethnicity may be more
diverse, and behaviour may differ in terms of outdoor work
and activities (Fig. 3). It is unclear why Northern Ireland has
a higher cSCC incidence compared with other nations; this
could relate to a higher number of outdoor occupations,
recent public health campaigns, variation in clinical practice or
data collection.31,32 Compared with elsewhere in the world,
incidence rates of KC in the U.K. are lower than those pub-
lished in Australia, but higher than elsewhere in Europe and
the U.S.A., with varying rates presumably due to skin type/ge-
netic predisposition and UVR exposure.6,10,18,24
Similar to previous studies, we show that BCC and cSCC are
both significantly associated with lower deprivation quin-
tiles.33 This is likely to be the result of the expense of foreign
travel and increased leisure time being more affordable in
these quintiles, equating to higher UVR exposure in the gen-
erations affected as well as increased awareness of skin cancer
and access to health care.
According to national statistics, 86% of the population in
England and Wales are of ‘white’ ethnicity; however, of those
with known ethnicity, 993% of patients with primary cSCC
are of white ethnicity, which may be mainly due to these skin
types having reduced protection from UVR.34
Three year net survival of KC is over 95% for both types
and the overall prognosis of KC is very good with only a
minority of patients with cSCC developing advanced disease.
Despite low mortality rates, KCs represent an overwhelming
tumour burden in the population.35 We confirm an interesting
observation that patients who develop their first BCC have a
3-year net survival of over 100%.36 This can be in part the
result of the association of BCC with lower deprivation quin-
tiles, fitness for biopsy excluding older more frail patients
from our cohort and general adherence to healthier outdoor
lifestyles. Figure 4 shows that at the age of 85 years a peak in
incidence rate occurs, suggesting that patients are excluded
where the risk outweighs the benefit for BCC treatment, i.e.
frailer, older patients with more comorbidities.
In conclusion, a new technique taking advantage of the
modernization of national cancer registration and data collec-
tion in the U.K. has resulted in significantly improved report-
ing of KC incidence. We have validated this registration and
data collection approach here and now demonstrate more
accurately the huge and steadily increasing trend in KC inci-
dence in the U.K. The scale of the disease burden posed by
KC inevitably has implications for healthcare resources. The
more accurate incidence data reported here, and now available
prospectively through improved KC registration, will undoubt-
edly facilitate improved service planning and provision in the
future. In addition, it will lead to improved understanding of
the natural history and prognosis of KC. Finally, it provides
further evidence for the importance of future skin cancer pre-
vention initiatives as part of strategies to reduce the morbidity
and future healthcare resource implications of KC.
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